Literature DB >> 20556757

Interventions for cellulitis and erysipelas.

Sally A Kilburn1, Peter Featherstone, Bernie Higgins, Richard Brindle.   

Abstract

BACKGROUND: Cellulitis and erysipelas are now usually considered manifestations of the same condition, a skin infection associated with severe pain and systemic symptoms. A range of antibiotic treatments are suggested in guidelines.
OBJECTIVES: To assess the efficacy and safety of interventions for non-surgically-acquired cellulitis. SEARCH STRATEGY: In May 2010 we searched for randomised controlled trials in the Cochrane Skin Group Specialised Register, the Cochrane Central Register of Controlled Trials in The Cochrane Library, MEDLINE, EMBASE, and the ongoing trials databases. SELECTION CRITERIA: We selected randomised controlled trials comparing two or more different interventions for cellulitis. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data. MAIN
RESULTS: We included 25 studies with a total of 2488 participants. Our primary outcome 'symptoms rated by participant or medical practitioner or proportion symptom-free' was commonly reported. No two trials examined the same drugs, therefore we grouped similar types of drugs together.Macrolides/streptogramins were found to be more effective than penicillin antibiotics (Risk ratio (RR) 0.84, 95% CI 0.73 to 0.97). In 3 trials involving 419 people, 2 of these studies used oral macrolide against intravenous (iv) penicillin demonstrating that oral therapies can be more effective than iv therapies (RR 0.85, 95% CI 0.73 to 0.98).Three studies with a total of 88 people comparing a penicillin with a cephalosporin showed no difference in treatment effect (RR 0.99, 95% CI 0.68 to 1.43).Six trials which included 538 people that compared different generations of cephalosporin, showed no difference in treatment effect (RR 1.00, 95% CI 0.94 to1.06).We found only small single studies for duration of antibiotic treatment, intramuscular versus intravenous route, the addition of corticosteroid to antibiotic treatment compared with antibiotic alone, and vibration therapy, so there was insufficient evidence to form conclusions. Only two studies investigated treatments for severe cellulitis and these selected different antibiotics for their comparisons, so we cannot make firm conclusions. AUTHORS'
CONCLUSIONS: We cannot define the best treatment for cellulitis and most recommendations are made on single trials. There is a need for trials to evaluate the efficacy of oral antibiotics against intravenous antibiotics in the community setting as there are service implications for cost and comfort.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20556757      PMCID: PMC8693180          DOI: 10.1002/14651858.CD004299.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  118 in total

1.  Ceftriaxone versus cefazolin with probenecid for severe skin and soft tissue infections.

Authors:  G Brown; R Chamberlain; J Goulding; A Clarke
Journal:  J Emerg Med       Date:  1996 Sep-Oct       Impact factor: 1.484

2.  Risk factors for erysipelas of the leg in Tunisia: a multicenter case-control study.

Authors:  Mourad Mokni; Alain Dupuy; Mohamed Denguezli; Raouf Dhaoui; Samir Bouassida; Montacer Amri; Sami Fenniche; Faten Zeglaoui; Nejib Doss; Rafiaa Nouira; Amel Ben Osman-Dhahri; Jamel Zili; Insaf Mokhtar; Mohamed Ridha Kamoun; Abdelmajid Zahaf; Olivier Chosidow
Journal:  Dermatology       Date:  2006       Impact factor: 5.366

3.  Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group.

Authors:  K J Tack; T W Littlejohn; G Mailloux; M M Wolf; C H Keyserling
Journal:  Clin Ther       Date:  1998 Mar-Apr       Impact factor: 3.393

4.  Recurrent erysipelas: predisposing factors and costs of prophylaxis.

Authors:  C Jorup-Rönström; S Britton
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

5.  Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.

Authors:  G Siami; N Christou; I Eiseman; K J Tack
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

6.  Imipenem versus standard therapy in the treatment of serious soft tissue infection.

Authors:  I M Gould; M Hudson; J Morris; G Page; J G Douglas; C C Smith; T M Reid
Journal:  Drugs Exp Clin Res       Date:  1988

7.  Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group.

Authors:  R L Nichols; D R Graham; S L Barriere; A Rodgers; S E Wilson; M Zervos; D L Dunn; B Kreter
Journal:  J Antimicrob Chemother       Date:  1999-08       Impact factor: 5.790

8.  Prospective randomized phase II study of intravenous cefpirome 1g or 2g bd in the treatment of hospitalized patients with different infections. Cefpirome Study Group.

Authors:  C Carbon
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

9.  Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis.

Authors:  Matthew J Hepburn; David P Dooley; Peter J Skidmore; Michael W Ellis; William F Starnes; William C Hasewinkle
Journal:  Arch Intern Med       Date:  2004 Aug 9-23

10.  The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas.

Authors:  P E Pertel; B I Eisenstein; A S Link; B Donfrid; E J A Biermann; P Bernardo; W J Martone
Journal:  Int J Clin Pract       Date:  2009-03       Impact factor: 2.503

View more
  23 in total

Review 1.  [Systemic therapy with antibiotics. Overview of important antibiotics in dermatology].

Authors:  C Sunderkötter; K Becker
Journal:  Hautarzt       Date:  2014-02       Impact factor: 0.751

2.  Over-admission and over-treatment of patients with cellulitis: a 5-year audit against international guidelines.

Authors:  Ailbhe Kiely; Sami Abd Elwahab; Declan McDonnell; Roisin Tully; Maria Randles; Mary Hickey; Felix Ofori-Kuma; Ivan Ivanovski; Suhail Khan; Karl Schmidt; Kenneth Mealy
Journal:  Ir J Med Sci       Date:  2019-08-14       Impact factor: 1.568

3.  Treatment failure definitions for non-purulent skin and soft tissue infections: a systematic review.

Authors:  Krishan Yadav; Avik Nath; Kathryn N Suh; Lindsey Sikora; Debra Eagles
Journal:  Infection       Date:  2019-08-05       Impact factor: 3.553

Review 4.  [Bacterial skin and soft tissue infections].

Authors:  Frank Hanses
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

5.  Variability of antimicrobial prescribing in patients with acute cellulitis.

Authors:  Matthew S Davies; Munro B Robertson; Stewart H A Brown; Bethan Saunders; W Stephen Waring
Journal:  Eur J Clin Pharmacol       Date:  2012-03-06       Impact factor: 2.953

6.  Meta-analysis of randomised trials comparing a penicillin or cephalosporin with a macrolide or lincosamide in the treatment of cellulitis or erysipelas.

Authors:  Athena Ferreira; Mark J Bolland; Mark G Thomas
Journal:  Infection       Date:  2016-04-16       Impact factor: 3.553

Review 7.  Infection in Venous Leg Ulcers: Considerations for Optimal Management in the Elderly.

Authors:  Douglas J Pugliese
Journal:  Drugs Aging       Date:  2016-02       Impact factor: 3.923

8.  Treatment Duration and Associated Outcomes for Skin and Soft Tissue Infections in Patients With Obesity or Heart Failure.

Authors:  Claudia Ihm; Jesse D Sutton; Tristan T Timbrook; Emily S Spivak
Journal:  Open Forum Infect Dis       Date:  2019-05-07       Impact factor: 3.835

9.  Oral flucloxacillin and phenoxymethylpenicillin versus flucloxacillin alone for the emergency department outpatient treatment of cellulitis: study protocol for a randomised controlled trial.

Authors:  Michael Quirke; Abel Wakai; Peadar Gilligan; Ronan O'Sullivan
Journal:  Trials       Date:  2013-06-03       Impact factor: 2.279

10.  Cellulitis in children: a retrospective single centre study from Australia.

Authors:  Elise Salleo; Conor I MacKay; Jeffrey Cannon; Barbara King; Asha C Bowen
Journal:  BMJ Paediatr Open       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.